Gannex Received U.S. FDA Fast Track Designation for Its NASH Drug Candidate ASC42,an FXR Agonist


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Gannex Received U.S. FDA Fast Track Designation for Its NASH Drug Candidate ASC42,an FXR Agonist
Gannex, announced today that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its non-alcoholic steatohepatitis (NASH) drug candidate ASC42.

Gannex, a wholly-owned company of Ascletis Pharma Inc. (HKEX:1672) and fully dedicated to the R&D and commercialization of new drugs in the field of NASH announced today that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its non-alcoholic steatohepatitis (NASH) drug candidate ASC42.

The U.S. FDA's Fast Track development program is designed to facilitate the development and expedite the review of drugs that have the ability to treat serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs with additional clinical benefits to patients. There are no FDA approved medicines for NASH indication yet. This Fast Track designation represents the FDA's recognition of ASC42's potential in addressing these unmet medical needs for NASH patients.

Gannex received the investigational new drug application (IND) approval for ASC42 from the U.S. FDA in October this year. ASC42 is an in-house developed,novel non-steroidal, selective, potent Farnesoid X Receptor (FXR) agonist with best-in-class potential. In two NASH animal models, ASC42 demonstrated significant improvements in liver steatosis, inflammation, and fibrosis. The oral tablet formulation of ASC42 has been developed with in-house proprietary technology and is stable at room temperature.

"We are thrilled that the FDA granted Fast Track designation for our FXR agonist ASC42 which is discovered and developed by our in-house talented R&D team," said Dr. Jinzi J. Wu, "This critical recognition by FDA will accelerate global development of ASC42, a potential best-in-class FXR agonist."

Gannex has two additional drug candidates at a clinical-stage in its NASH pipeline, ASC40, and ASC41. ASC40(TVB-2640), an oral fatty acid synthase (FASN) inhibitor, has been shown to significantly reduce liver fat with a 61% responder rate in the 50 mg group in Phase II clinical trial (FASCINATE-1). ASC41 is a liver-targeted prodrug and its active moiety (ASC41-A) is selective for thyroid hormone receptor β (THR-β) and currently, in phase, I study. In addition to three clinical-stage drug candidates against three different NASH targets, Gannex is developing three pre-clinical stage combination therapies, namely ASC40/ASC42, ASC41/ASC42, and ASC40/ASC41 combination therapies.

About Ascletis

Ascletis is an innovative R&D driven biotech and listed on the Hong Kong Stock Exchange (1672.HK). Ascletis is committed to developing and commercializing innovative drugs in the areas of viral hepatitis, NASH, and HIV/AIDS for unmet medical needs in China and globally. Led by a management team with deep expertise and a proven track record, Ascletis has developed into a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization.

Ascletis has three marketed products and thirteen R&D pipeline drug candidates or combination therapies (nine of them developed in-house).

1. Viral hepatitis: 

(i) Hepatitis B: focus on breakthrough therapies for HBV clinical cure with subcutaneously injected PD-L1 antibody - ASC22 and Pegasys® as cornerstone drugs.

(ii) Hepatitis C: successfully launched all-oral regimen of Asclevir® and Ganovo® combination (RDV/DNV regimen), and ASC18 fixed-dose combination (FDC) is an upgraded version of RDV/DNV regimen with bridging study finished.

2. NASH:

Gannex, a wholly-owned company of Ascletis, is fully dedicated to the R&D and commercialization of new drugs in the field of NASH. Gannex has three clinical-stage drug candidates against three different targets – FASN, THR-beta, and FXR, and three pre-clinical stage combination therapies.

3. HIV/AIDS: ASC09F is an FDC treatment of HIV targeting protease. The clinical trial application of ASC09F has been approved.

Tags : #GannexUpdates14Dec2020 #Gannex #AscletisPharma #NASH #FDA #DrugCandidateASC42 #ASC42 #DrJinziJWu #Ascletis #ASC09F #Diseases #FXRAgonist

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026